Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
Exelixis stock last closed at $36.19, up 0.11% from the previous day, and has increased 58.24% in one year. It has overperformed other stocks in the Biotechnology industry by 1.37 percentage points. Exelixis stock is currently +79.69% from its 52-week low of $20.14, and -9.57% from its 52-week high of $40.02.
As of Apr 17, 2025, there are 279.88M shares of EXEL outstanding. The market cap of EXEL is $10.13B. In the past 24 hours, 2.26M EXEL shares were traded.
How to Buy Exelixis Stock
Wondering how to invest in Exelixis stock? Here's how.
Choose where to buy Exelixis stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Exelixis stock.
Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
Put funds into your brokerage account: Choose your method of payment and add your information.
Analyze Exelixis stock: The Exelixis ticker symbol is EXEL. Is Exelixis stock a good investment? Should you buy shares of EXEL? How do EXEL's underlying business fundamentals look? Do top analysts think Exelixis is a good buy? Why has EXEL's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if EXEL is a good stock to buy).
Execute your EXEL trade: Decide if you will purchase EXEL shares at the current market price or use a limit order to purchase EXEL stock at a particular price.
Watch your EXEL position: Create a watchlist to track your investment in Exelixis shares.
Step 1: Choose where to buy Exelixis stock
You will need a brokerage account in order to access the NASDAQ market and buy EXEL stock.
A brokerage account is an investment account that enables you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to global financial markets: From Tech to Financial Services, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal details so you can invest in EXEL stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Exelixis stock
After you have identified the best place to buy Exelixis stock, it's crucial to research their stock before you invest, so you can comprehend the risk and upside.
Exelixis Metrics
EXEL Price
$36.19
1w %
5.02%
1y %
58.24%
5y %
86.16%
P/E
20.11x
P/B
4.51x
P/S
4.84x
PEG
0.89x
Revenue
$2.17B
Earnings
$521.27M
Fore. Rev. Growth
10.51%
Fore. Earn. Growth
22.66%
Market Cap
$10.13B
Next Earnings
Apr 28, 2025
Next Dividend
N/A
Exelixis Due Diligence Checks
WallStreetZen was created to help average investors perform better fundamental analysis quickly.
There are more short-term assets than short-term liabilities on the EXEL balance sheet.
There are more short-term assets than long-term liabilities on the EXEL balance sheet.
EXEL's operating cash flow of $699.97M allows it to safely service it's debt of $190.82M.
EXEL earnings of $681.64M is not enough to cover its interest payments.
EXEL profit margin has gone up from 11.4% to 24% in the past year.
EXEL has a low debt to equity ratio of 0.31.
Negative Health Checks:
Total EXEL debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy Exelixis stock
Out of 17 Wall Street analysts who give forecasts on EXEL, the consensus analyst rating on EXEL is a Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest EXEL Analyst Recommendations
David Lebovitz, a bottom 11% analyst from Citigroup maintains EXEL with a strong buy rating and raises their EXEL price target from $38.00 to $45.00, on Feb 12, 2025.
Michael Schmidt, a top 31% analyst from Guggenheim reiterates EXEL with a strong buy rating and maintains their EXEL price target from $42.00 to $42.00, on Feb 12, 2025.
Sudan Loganathan, a bottom 2% analyst from Stephens & Co. reiterates EXEL with a hold rating and maintains their EXEL price target from $29.00 to $29.00, on Feb 12, 2025.
Stephen Willey, a bottom 4% analyst from Stifel Nicolaus maintains EXEL with a hold rating and raises their EXEL price target from $30.00 to $36.00, on Feb 12, 2025.
Joseph Catanzaro, a bottom 2% analyst from Piper Sandler maintains EXEL with a strong buy rating and raises their EXEL price target from $37.00 to $38.00, on Feb 12, 2025.
Last year, EXEL earnings were $521.27M. Over the last five year, EXEL's earnings have increased by 11.17% per year. This was faster than the Biotechnology industry average of 10.71%.
Last year, EXEL revenue was $2.17B. Over the last five year, EXEL's revenue has gone up by 17.51% per year. This was slower than the Biotechnology industry average of 44.43%.
No, Exelixis doesn't provide an income stream by paying out dividends.
What others are saying about EXEL
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your EXEL trade
You have two primary types of orders:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are mostly the best for newer investors.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to make sure you're buying or selling at a particular price limit, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you need more help with buying stocks on eToro, watch the helpful video below:
As of Apr 17, 2025, it costs $36.19 to buy one share of Exelixis stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.276 shares of EXEL.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.